EMA Grants Orphan Drug Designation to Maresin-1 Compound for Spinal Cord Injury Treatment
The European Medicines Agency (EMA) has granted orphan drug designation to a compound based on Maresin-1 (MaR1) for the treatment of spinal cord injuries. This promising compound is currently under investigation by a research team from the Universitat Autònoma de Barcelona (UAB).
This designation acknowledges that MaR1 could offer a relevant clinical benefit in an area with substantial unmet medical need, representing a development milestone for a potential new treatment.
The Unmet Need in Spinal Cord Injury Treatment
Spinal cord injuries affect an estimated 20 to 45 cases per million inhabitants annually. The significant impact of these injuries is compounded by a critical gap in treatment options.
There is currently no pharmacological treatment that enhances neurological recovery post-injury. While Methylprednisolone is approved for the acute phase, its use is often discouraged due to limited efficacy and significant adverse effects.
Maresin-1: A Promising Approach
MaR1 is a lipid naturally produced by macrophages, known for its role in promoting the resolution of inflammation and providing tissue protection. Research conducted by the UAB's Neuroplasticity and Regeneration Group, led by Rubèn López-Vales, has yielded encouraging results in animal models.
This research indicates that MaR1 significantly reduces post-injury inflammation and supports processes that limit neurodegeneration, leading to improved locomotion recovery in animal models.
Rubèn López-Vales stated that this designation acknowledges years of research and facilitates progress toward offering therapy to individuals affected by spinal cord injuries.
Advantages of Orphan Drug Designation
The orphan drug designation from the EMA offers substantial advantages for the development of MaR1. These include priority scientific advice and accelerated evaluation pathways, which can significantly streamline the regulatory process.
Crucially, it also grants marketing exclusivity if the compound successfully reaches the market, providing an incentive for further investment and development.
The Path Ahead: From Preclinical to Clinical Trials
Progression towards a clinical trial for MaR1 is a multi-step process. It requires the completion of regulatory preclinical studies to establish the product's safety profile and the development of a validated manufacturing process. Additionally, approval from regulatory agencies and ethics committees for all presented documentation is essential.
These crucial steps are estimated to take approximately 3 to 5 years before patient trials can commence.
The UAB research behind MaR1 is supported by funding from various institutions, including the Spanish Ministry of Science, Innovation and Universities, the "la Caixa" Foundation, the Agency for the Management of University and Research Grants (AGAUR), Barcelona Activa, and UAB's own funds.